TrialBritish journal of haematology2022

Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.

Alessandra Larocca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.